Hit Identification & Confirmation

Our expertise in hit identification & confirmation

CYTOO supports the identification and confirmation of small molecules, biologics, or gene therapies that modulate disease-relevant phenotypes in skeletal muscle. Our platform enables robust, reproducible hit discovery aligned with disease biology and clinical relevance.

Our approach

Using our MyoScreen platform, we perform phenotypic or target-based high-content screening, combining disease-relevant assays with automated image acquisition and AI-powered analysis.

We screen diverse compound libraries on patient-derived models and confirm hits through orthogonal readouts and multi-donor validation.

Our assays are designed to detect subtle but meaningful phenotypic shifts that are often missed by traditional approaches.

We ensure high-confidence hit confirmation with translational potential.

Case study

Phenotypic screening to address muscle wasting

Metabolic and chronic diseases such as sarcopenia, type 2 diabetes, cachexia, or chronic kidney disease often lead to progressive muscle loss.

Our objective was to identify novel compounds that prevent, slow-down, or reverse muscle wasting.

We performed high-content screening in human myotubes using a robust hypertrophy assay (Z’ > 0.3; CV < 15%).

Multiple active hits were identified, including CYT9733, which consistently increased myotube size across 5 independent donors.

How can we work together

Everything is tailored to your needs through a flexible R&D partnership model that fosters true collaboration and innovation. We offer adaptable project structures and FTE allocation to fit your goals.

In cases of joint development, outlicensing opportunities are also available for our MyoScreen™ technology, including assays and customised image analysis scripts.